PXSLY -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 months ago

    Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

    Pharmaxis to receive €18 million milestone payment in a significant further endorsement of the company's ability to generate value from its early stage pipeline. INGELHEIM, Germany and SYDNEY, Aug. 25, 2017 /PRNewswire/ -- Boehringer Ingelheim and pharmaceutical company Pharmaxis (PXS.AX) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

  • PR Newswire4 months ago

    Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

    Pharmaxis to receive €18 million milestone payment in a significant further endorsement of the company's ability to generate value from its early stage pipeline. INGELHEIM, Germany and SYDNEY, Aug. 24, 2017 /PRNewswire/ -- Boehringer Ingelheim and pharmaceutical company Pharmaxis (PXS.AX) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

  • Pharmaxis Ltd. :PXSLY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 14, 2017
    Capital Cube4 months ago

    Pharmaxis Ltd. :PXSLY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 14, 2017

    Categories: Yahoo FinanceGet free summary analysis Pharmaxis Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Pharmaxis Ltd. – Innoviva, Inc., Aradigm Corporation, Quintiles IMS Holdings, Inc. and Rigel Pharmaceuticals, Inc. (INVA-US, ARDM-US, Q-US and RIGL-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • PR Newswire9 months ago

    Synairgen plc: Additional Positive Data in Lung Fibrosis

    SOUTHAMPTON, England, March 10, 2017 /PRNewswire/ -- - Phase I c linical trial s cheduled to start in H2 2017   Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces ...